11 research outputs found
The Profile of a decent citizen: self-evaluations of citizens
fi=vertaisarvioitu|en=peerReviewed
Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
We sought to evaluate outcomes, costs of care, quality of life and predictors at 12 months in patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and evaluated use of optimal secondary prevention therapy, defined as use of aspirin and clopidogrel along with ⼠3 of the following 4 therapies at both hospital discharge and at one-year post-PCI: statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet.Journal ArticleResearch Support, Non-U.S. Gov'tSCOPUS: ar.jinfo:eu-repo/semantics/publishe
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-016-0224-5"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional enhanced
digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides<u></u></p
Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI.
Despite common European Society of Cardiology recommendations, adherence to guideline therapy varies, both temporally and geographically. We sought to examine current differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).Comparative StudyJournal ArticleMulticenter StudyResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe
The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0321-0"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced content for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced content for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as âpeer reviewedâ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides</p>
<p> </p
Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
<p></p><p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s13300-018-0396-2">https://link.springer.com/article/10.1007/s13300-018-0396-2</a></p><p></p><p></p><p>
</p><p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âÂÂmailto:[email protected]âÂÂ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>⢠Slide decks</p>
<p>⢠Videos and animations</p>
<p>⢠Audio abstracts</p>
<p>⢠Audio slides</p><br><p></p
Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study
Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy
Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: Results from the antiplatelet treatment observational registries (APTOR)
We sought to evaluate outcomes, costs of care, quality of life and predictors at 12 months in patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and evaluated use of optimal secondary prevention therapy, defined as use of aspirin and clopidogrel along with ⼠3 of the following 4 therapies at both hospital discharge and at one-year post-PCI: statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet.Journal ArticleResearch Support, Non-U.S. Gov'tSCOPUS: ar.jinfo:eu-repo/semantics/publishe